ISI (Twist Bioscience) was listed on the Nasdaq stock exchange, and Barclays raised its price target on the company on July 9, 2026.
3 reports, 1 independent
Updated Aug 19
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ISI (Twist Bioscience) was listed on the Nasdaq stock exchange, and Barclays raised its price target on the company on July 9, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- ISI
-
Twist Bioscience
Biotechnology company
-
Barclays
British bank
- QinetiQ carried out share purchases and arranged for a share buyback execution on the London Stock Exchange.
- Financial institutions provided ratings on multiple companies on July 8, 2026, including Goldman Sachs reiterating Tesla as neutral, Barclays initiating Toast as overweight, and Bank of America rating Nvidia as a buy.
Related events
- Barclays raised its price target on Latham Group on September 1, 2026.
- ISI raised price target to $380, driven by renewed patent licensing agreements between Apple and Qualcomm, and strong iPhone 18 demand.
- ISI and BNP Paribas recently trimmed price targets, with BNP Paribas also mentioned alongside Corona.
- Barclays raised S&P 500 price targets, noting that both Meta and Amazon are major Big Tech companies and are expected to contribute significantly to capital expenditures (CapEx).
- Barclays maintained Overweight rating and raised price target on August 29, 2025.